Metabolic syndrome seen in olanzapine group was 5.8%, in which symptoms of hypertriglyceridemia were seen in 42.3%, HDL-cholesterol reduction was seen in 30.8% of patients, waist circumference accounted for 21% .15%, blood glucose accounted for 19.2%, blood pressure accounted for 7.7%.